• Facebook
  • X
  • Instagram
MYELOMA360
  • Home
  • MYInsights
  • MYBoard
  • Strategy & Consulting
Select Page

by MM360 Staff | Dec 24, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More

Vyriad targets 2026 clinical trial for new experimental cell therapy VV169

by Marisa Wexler, MS | Dec 23, 2025 | Myeloma News

VV169, an experimental cellular therapy being developed by Vyriad to treat myeloma, is expected to enter clinical testing in 2026, the company announced. Earlier this month at the 67th annual meeting of the American Society of Hematology (ASH), Vyriad presented...

Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma

by MM360 Staff | Dec 23, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases

by MM360 Staff | Dec 23, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma

by MM360 Staff | Dec 23, 2025 | Myeloma News

Source: Myeloma : nature.com subject feeds Post Content Read More

by MM360 Staff | Dec 23, 2025 | Myeloma News

Source: Pharmacy Times articles Post Content Read More
« Older Entries

Recent Content

  • (no title)
  • (no title)
  • Trial offers ‘a light’ for patients with extramedullary myeloma
  • Expanding access to care in multiple myeloma
  • (no title)
  • Vyriad targets 2026 clinical trial for new experimental cell therapy VV169
  • Structured whole-body MRI highlights clinically relevant disease pattern changes in relapsed/refractory multiple myeloma
  • Secondary malignancy of T-cell origin after CAR T-cell therapy: EMA’s conclusions from the evaluation of 38 suspected cases
  • Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma
  • (no title)
  • Facebook
  • X
  • Instagram
©2016-2025 MYELOMA360 & Connect BioMed
We use cookies on our website to give you the most relevant experience by remembering your preferences and repeat visits. By clicking “Accept”, you consent to the use of ALL the cookies.
Do not sell my personal information.
SettingsAccept
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may have an effect on your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT